Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
1.
Rhinology ; 61(6): 508-518, 2023 Dec 01.
Article de Anglais | MEDLINE | ID: mdl-37703531

RÉSUMÉ

This meta-analysis aims to investigate the outcome of sinonasal adenoid cystic carcinoma (snAdCC). We followed PRISMA guidelines and included studies reporting 5-year overall survival (OS) rates for snAdCC. Eligible studies were identified through a literature search and assessed using JBI critical appraisal checklist. A total of 17 studies were included comprising 2259 patients (mean age: 58.1 years, 52.7% female, 47.3% male). The meta-analysis demonstrated that the 5-year OS, 10-year OS, and 5-year disease-free survival (DFS) were 68%, 40%, and 47.2%, respectively. Descriptive statistics on study level showed high rates of locally advanced tumor stages at diagnosis: 23% cT3, 53% cT4, 3.4% N+, and 4.2% M+. 29.7% of the tumors were in the nasal cavity, 67.6% in the paranasal sinuses. The maxillary, ethmoid, sphenoid, and frontal sinus were affected in 50.9%, 7.2%, 4%, and 0.5%, of cases. A combination of surgery and radiotherapy was used in 45.4% of the patients and 19.3% of patients received surgery only. In conclusion, these findings emphasize the significance of thorough surveillance for individuals with snAdCC to identify any potential recurrence or progression of the disease.


Sujet(s)
Carcinome adénoïde kystique , Sinus frontal , Tumeurs du nez , Tumeurs des sinus de la face , Humains , Mâle , Femelle , Adulte d'âge moyen , Carcinome adénoïde kystique/anatomopathologie , Carcinome adénoïde kystique/radiothérapie , Tumeurs des sinus de la face/thérapie , Tumeurs des sinus de la face/anatomopathologie , Tumeurs du nez/anatomopathologie , Études rétrospectives , Sinus frontal/anatomopathologie
2.
J Laryngol Otol ; 137(5): 551-555, 2023 May.
Article de Anglais | MEDLINE | ID: mdl-35729688

RÉSUMÉ

OBJECTIVE: The added value of hybrid positron emission tomography is increasingly recognised in head and neck cancer. However, its potential role in salivary gland carcinomas has been scarcely investigated. METHODS: A consecutive cohort of 45 salivary gland carcinoma patients who underwent pre-therapeutic hybrid positron emission tomography and surgical resection was reviewed. This study investigated whether maximum standardised uptake value correlated with tumour phenotype. RESULTS: Tumours of high-grade disease on histology (salivary duct carcinoma, carcinoma ex pleomorphic adenoma) had higher maximum standardised uptake value (Kruskal-Wallis test, p = 0.011) than low-grade tumours (adenoid cystic carcinoma and acinic cell carcinoma). Patients with pathologically confirmed node-positive disease had significantly higher maximum standardised uptake value of the primary tumour than patients with pathologically confirmed node-negative disease (Kruskal-Wallis test, p = 0.012). CONCLUSION: Maximum standardised uptake value of the primary tumour may guide clinical decision-making in patients with salivary gland carcinomas, as a high maximum standardised uptake value is associated with high-grade tumour histology and the presence of lymph node metastases. Clinicians may consider more aggressive surgery for these patients.


Sujet(s)
Adénome pléomorphe , Carcinome adénoïde kystique , Tumeurs des glandes salivaires , Humains , Tumeurs des glandes salivaires/imagerie diagnostique , Tumeurs des glandes salivaires/chirurgie , Tumeurs des glandes salivaires/anatomopathologie , Tomographie par émission de positons/méthodes , Adénome pléomorphe/imagerie diagnostique , Adénome pléomorphe/chirurgie , Carcinome adénoïde kystique/anatomopathologie , Glandes salivaires/anatomopathologie , Fluorodésoxyglucose F18
3.
Urology ; 156: 147-153, 2021 10.
Article de Anglais | MEDLINE | ID: mdl-34186136

RÉSUMÉ

OBJECTIVE: To report feasibility and outcome of salvage robotic-assisted laparoscopic radical prostatectomy (S-RALP) after focal therapy using high-intensity focused ultrasound (HIFU) treatment compared to primary robotic-assisted laparoscopic radical prostatectomy (pRALP). METHODS: In this bicentric trial patients undergoing S-RALP for detection of WHO2016/ISUP Grade Group 2 or 3 prostate cancer were previously treated in prospective focal HIFU trials. Perioperative data, complications, oncological and functional outcome were analysed. Patients who underwent pRALP were matched in a ratio 2(pRALP):1(S-RALP) according to preoperatively functional, oncological and clinical parameters. RESULTS: A total of 39 patients were included in the study (13S-RALP, 26pRALP). Median operative time in the S-RALP group was 260minutes (pRALP: 257minutes), blood loss was 230ml (pRALP: 300ml). Complications occurred in 46.2% (6/13) of S-RALP patients (pRALP: 26.9%), including four Clavien-Dindo III complications (pRALP: 2/26). In S-RALP adverse histological outcome (≥pT3a, pN+ or R1) was detected in 23.1% (3/13) (pRALP: 26.9%). There was one patient with PSA-persistence (pRALP: 2/26). Regarding functional outcomes there was no difference between the two groups observed (incontinence P=.71, erectile function P=.21). CONCLUSION: S-RALP should be offered to patients with an early relapse after focal HIFU. The early oncological outcome is satisfactory and functional outcome one year postoperatively is similar to pRALP. However, S-RALP is associated with a higher rate of Clavien-Dindo III complications (mainly, placement of a drainage), of which patients should be informed beforehand.


Sujet(s)
Dysfonctionnement érectile , Traitement par ondes de choc extracorporelles/méthodes , Complications postopératoires , Prostatectomie , Tumeurs de la prostate , Interventions chirurgicales robotisées , Thérapie de rattrapage , Incontinence urinaire , Perte sanguine peropératoire/statistiques et données numériques , Association thérapeutique/méthodes , Recherche comparative sur l'efficacité , Dysfonctionnement érectile/diagnostic , Dysfonctionnement érectile/étiologie , Humains , Mâle , Adulte d'âge moyen , Stadification tumorale , Évaluation des résultats et des processus en soins de santé , Complications postopératoires/étiologie , Complications postopératoires/thérapie , Antigène spécifique de la prostate/analyse , Prostatectomie/effets indésirables , Prostatectomie/méthodes , Tumeurs de la prostate/sang , Tumeurs de la prostate/anatomopathologie , Tumeurs de la prostate/physiopathologie , Tumeurs de la prostate/thérapie , Interventions chirurgicales robotisées/effets indésirables , Interventions chirurgicales robotisées/méthodes , Thérapie de rattrapage/effets indésirables , Thérapie de rattrapage/méthodes , Incontinence urinaire/diagnostic , Incontinence urinaire/étiologie
4.
Urologe A ; 59(2): 135-141, 2020 Feb.
Article de Allemand | MEDLINE | ID: mdl-31974661

RÉSUMÉ

BACKGROUND: In recent years, the characterization of different renal cell carcinoma entities has significantly improved, in particular due to molecular typing. OBJECTIVES: Classical, accepted and emerging renal cell carcinoma entities are described. MATERIALS AND METHODS: A literature search was performed, followed by evaluation and description of the literature focusing on different renal cell carcinoma entities. RESULTS: Classical renal cell carcinoma entities such as clear cell carcinoma, papillary renal cell carcinoma and chromophobe renal cell carcinoma have been expanded in particular by molecular techniques to include, for example, translocation carcinoma or carcinoma with mutations in genes of the mitochondrial energy metabolism. Some rare entities have been accepted by the World Health Organization (WHO) classification, while some are considered as emerging entities. CONCLUSIONS: A range of newly accepted and emerging renal cell carcinoma entities have been introduced in the 2016 WHO classification. A precise and correct diagnosis is of major importance regarding the prognostic assessment, potential new therapeutic strategies and possible hereditary associations.


Sujet(s)
Néphrocarcinome/classification , Néphrocarcinome/anatomopathologie , Tumeurs du rein/classification , Tumeurs du rein/anatomopathologie , Léiomyomatose/anatomopathologie , Néphrocarcinome/génétique , Humains , Rein/anatomopathologie , Tumeurs du rein/génétique , Pronostic , Translocation génétique , Organisation mondiale de la santé
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE